STAAR SURGICAL CO — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
STAAR appointed Warren Foust as President and CEO effective August 4, 2026, with annual base salary of $730,000. Foust receives equity awards totaling ~594,000 shares (131,830 + 40,471 + 22,493 performance/time-vesting options and RSUs in CEO grant; plus 263,664 + 80,942 + 44,986 in 2027 grant), exercisable at $24.12/share with stock-price hurdles of $50–$100. Deborah Andrews transitions from Interim Co-CEO to EVP and CFO. Board expanded by one seat for Foust.
Why this rating
CEO succession with internal promotion; material equity grant (~$14–16M at current price) is ~1.6–1.8% of $884M market cap; executive continuity and profitable growth momentum signaled by management statements support positive sentiment.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.